AstraZeneca PLC (AZN)
| Market Cap | 216.45B |
| Revenue (ttm) | 54.98B |
| Net Income (ttm) | 7.77B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.97 |
| PE Ratio | 27.85 |
| Forward PE | 14.97 |
| Dividend | $1.52 (2.18%) |
| Ex-Dividend Date | Feb 21, 2025 |
| Volume | 4,023,466 |
| Open | 70.20 |
| Previous Close | 70.54 |
| Day's Range | 69.65 - 70.22 |
| 52-Week Range | 61.24 - 87.68 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 95.00 (+36.34%) |
| Earnings Date | Jul 24, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price forecast is $95.0, which is an increase of 36.34% from the latest price.
News
AstraZeneca's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S.
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a Phase 2 trial. The approval was also supported by data from a Phase 3 trial...
US approves AstraZeneca, Daiichi's treatment for lung cancer
AstraZeneca said on Tuesday that U.S. regulators have approved its precision drug Datroway to treat a type of lung cancer, adding that the drugmaker would now pay partner Daiichi Sankyo $45 million in...
5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List
I highlight 15 dividend-paying stocks from Bloomberg's 50 Companies to Watch that meet my 'safer' criteria: free cash flow yields exceed dividend yields. The top ten dividend focus stocks offer an est...
AstraZeneca Teams Up With CSPC Pharmaceuticals With Deal Valued at Up to $5.33 Billion
The deal with China's CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of new drug candidates.
AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC
AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.
AstraZeneca CEO: We totally agree with President Trump on this
AstraZeneca CEO Pascal Soriot unpacks President Donald Trump's drug cost cut executive order on 'The Claman Countdown.' #foxbusiness #health #trump #maha
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
AstraZeneca CEO Pascal Soriot on breast cancer drug trial
Pascal Soriot, CEO of AstraZeneca, said on Monday that he sees the pharma company's breast cancer blood test, which tracks signs of returning cancer, as "the future of cancer treatment."
AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment
CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation, ...
Experimental AstraZeneca pill helps cut risk of breast cancer progression
CNBC's Joe Kernen reports on the latest news.
'Transformational' new drug could stop breast cancer tumours before they grow, trial finds
A new drug could stop some breast cancer tumours from using hormones to grow, a trial has found.
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding...
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbocic...
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid...
Why AstraZeneca May Be 2025's Most Underrated Pharma Stock
In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective HER2-direc...
Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health and AstraZeneca announce licensing agreement to develop AI-powered screening algorithms for early disease detection.
AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American S...
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the BATURA Phase IIIb trial showed AstraZeneca's anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated ...
35 Barron's Pro-Picks: One Ideal May DiviDog
Barron's interviewed eleven financial industry Roundtable-pros who tapped 65 predictions. Six non-ADR foreign-stocks and four mutual funds were dropped by YCharts screens of active US listings, leavin...
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma
Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical respo...
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoraci...
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'
President plans to use executive powers, saying US should pay ‘same price as nation that pays the lowest price'
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG inductio...